| Study . | Treatment . | 1-Year Outcomes . | . |
|---|---|---|---|
| . | . | Local Control . | Distant Brain Control . |
| RTOG 95–084 | WBRT | 71% | 67% |
| WBRT + SRS | 82% | 73% | |
| EORTC 229525 | SRS | 70% | 56% |
| WBRT + SRS | 87% | 72% | |
| MDACC6 | SRS | 67% | 45% |
| WBRT + SRS | 100% | 73% | |
| JROSG-99–17 | SRS | 76% | 37% |
| WBRT + SRS | 90% | 58% | |
| Alliance N05748 | SRS | 73% | 70% |
| WBRT + SRS | 90% | 92% | |
| Summary of WBRT + SRS Arms | 82–100% | 58–92% | |
| Popp et al9 | HA-WBRT 30 Gy/12 fx + SIB 51Gy/42Gy/12 fx for metastases/resection cavities | 98% | 69% |
| Westover et al3 | HA-WBRT 20 Gy/10 fx + SIB 40 Gy/10 fx for metastases | 91% | 87% |
| Study . | Treatment . | 1-Year Outcomes . | . |
|---|---|---|---|
| . | . | Local Control . | Distant Brain Control . |
| RTOG 95–084 | WBRT | 71% | 67% |
| WBRT + SRS | 82% | 73% | |
| EORTC 229525 | SRS | 70% | 56% |
| WBRT + SRS | 87% | 72% | |
| MDACC6 | SRS | 67% | 45% |
| WBRT + SRS | 100% | 73% | |
| JROSG-99–17 | SRS | 76% | 37% |
| WBRT + SRS | 90% | 58% | |
| Alliance N05748 | SRS | 73% | 70% |
| WBRT + SRS | 90% | 92% | |
| Summary of WBRT + SRS Arms | 82–100% | 58–92% | |
| Popp et al9 | HA-WBRT 30 Gy/12 fx + SIB 51Gy/42Gy/12 fx for metastases/resection cavities | 98% | 69% |
| Westover et al3 | HA-WBRT 20 Gy/10 fx + SIB 40 Gy/10 fx for metastases | 91% | 87% |
| Study . | Treatment . | 1-Year Outcomes . | . |
|---|---|---|---|
| . | . | Local Control . | Distant Brain Control . |
| RTOG 95–084 | WBRT | 71% | 67% |
| WBRT + SRS | 82% | 73% | |
| EORTC 229525 | SRS | 70% | 56% |
| WBRT + SRS | 87% | 72% | |
| MDACC6 | SRS | 67% | 45% |
| WBRT + SRS | 100% | 73% | |
| JROSG-99–17 | SRS | 76% | 37% |
| WBRT + SRS | 90% | 58% | |
| Alliance N05748 | SRS | 73% | 70% |
| WBRT + SRS | 90% | 92% | |
| Summary of WBRT + SRS Arms | 82–100% | 58–92% | |
| Popp et al9 | HA-WBRT 30 Gy/12 fx + SIB 51Gy/42Gy/12 fx for metastases/resection cavities | 98% | 69% |
| Westover et al3 | HA-WBRT 20 Gy/10 fx + SIB 40 Gy/10 fx for metastases | 91% | 87% |
| Study . | Treatment . | 1-Year Outcomes . | . |
|---|---|---|---|
| . | . | Local Control . | Distant Brain Control . |
| RTOG 95–084 | WBRT | 71% | 67% |
| WBRT + SRS | 82% | 73% | |
| EORTC 229525 | SRS | 70% | 56% |
| WBRT + SRS | 87% | 72% | |
| MDACC6 | SRS | 67% | 45% |
| WBRT + SRS | 100% | 73% | |
| JROSG-99–17 | SRS | 76% | 37% |
| WBRT + SRS | 90% | 58% | |
| Alliance N05748 | SRS | 73% | 70% |
| WBRT + SRS | 90% | 92% | |
| Summary of WBRT + SRS Arms | 82–100% | 58–92% | |
| Popp et al9 | HA-WBRT 30 Gy/12 fx + SIB 51Gy/42Gy/12 fx for metastases/resection cavities | 98% | 69% |
| Westover et al3 | HA-WBRT 20 Gy/10 fx + SIB 40 Gy/10 fx for metastases | 91% | 87% |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
